Summary of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings on May 17, 2018

May 17, 2018 - By Frank Plummer

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Corporate Logo

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Ratings Coverage

A total of 3 analysts rate Fresenius Medical Care (NYSE:FMS) as follows: 2 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 67% are bullish. (NYSE:FMS) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. On Tuesday, April 24 the stock of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has “Buy” rating given by Deutsche Bank. On Wednesday, December 20 SunTrust maintained Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) rating. SunTrust has “Buy” rating and $62.0 target. In Monday, December 11 report Morgan Stanley downgraded the stock to “Equal-Weight” rating. Listed here are Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PTs and latest ratings.

24/04/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade

FMS hit $51.625 during the last trading session after $0.975 change.Currently Fresenius Medical Care AG & Co. KGaA is uptrending after 18.90% change in last May 17, 2017. FMS has 4,184 shares volume. The stock outperformed the S&P500 by 7.35%.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services.The firm is worth $31.73 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.The P/E ratio is 20.63. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.

A couple more Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) news were announced by: which released on April 23, 2018 “24 Stocks Moving In Monday’s Pre-Market Session”, also on May 03, 2018 announced “Fresenius Medical Care AG & Co. KGaA (FMS) Q1 2018 Results – Earnings Call Transcript”, the next is “Why Chicago Bridge & Iron, Akorn, and Flotek Industries Slumped Today” on April 23, 2018. has article titled “Why Akorn, Inc.’s Stock Is Up Big Today”.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.